

Outperform → | Target Price : € 16.0


Price (22/08/2025) : € 10.35 | Upside : 55%

 Révision
 12/25e
 12/26e

 EPS
 18.3%
 0.8%

## Positive development in H1 2025

Publication date: 25/08/2025 06:00 Writing date: 22/08/2025 14:34



Sources: ODDO BHF Securities, SIX

Share data		
TPG GY   TPGG.DE		
Market Cap (€m)		211
Enterprise value (€m)		323
Extrema 12 months (€)	7.20 _	12.90
Free Float (%)		20.1

Performance (%)	1m	3m	12m
Absolute	9.6	-10.4	20.1
Perf. rel. Country Index	14.2	-5.8	23.8
Perf. rel. SDAX	12.8	-14.5	-3.4

Pert. rei. SDAX	12.8	-14.5	-3.4
P&L	12/25e	12/26e	12/27e
Sales (€m)	717	802	839
EBITDA (€m)	79.7	60.3	65.4
Current EBIT (€m)	69.8	50.4	55.4
Attr. net profit (€m)	47.4	27.5	31.0
Adjusted EPS (€)	2.32	1.35	1.52
Dividend (€)	0.00	0.00	0.00
P/E (x)	4.5	7.7	6.8
P/B (x)	0.9	0.9	0.8
Dividend Yield (%)	0.0	0.0	0.0
FCF yield (%)	10.6	17.0	14.4
EV/Sales (x)	0.45	0.39	0.37
EV/EBITDA (x)	4.1	5.2	4.8
EV/Current EBIT (x)	4.6	6.2	5.6
Gearing (%)	48	43	37
Net Debt/EBITDA (x)	1.4	1.7	1.5

Next	Events

14/11/2025 Q3 Results

## Strong improvement in key figures

During H1 2025, TPG has generated a substantial increase in GMV (gross merchandise volume), net sales and adjusted EBITDA. Whereas GMV and net sales were in line with our estimates, adjusted EBITDA came in stronger than expected. GMV rose by 47.4% to € 652.1m (+1.0% vs ODDO BHFe) and net sales by 48.2% to € 343.0m (-0.7% vs ODDO BHFe). Organic growth was 59% in H1 2025 (vs 43% in FY 2024). Growth in GMV and net sales was due to: 1/ an increase of 25.8% in the number of connected partners to 15,781 and 2/ the successful expansion of the platform and software solutions to 27 industries. Seven acquisitions were made in the six months of 2025 (Lyra Pet, Fintus, Herbertz, JoliCloset, Beste Aussichten, Karrasch & Nolte, Freudenhaus Optik), of which the Lyra Pet, Herbertz, Joli Closet and Fintus acquisitions were already consolidated in the reporting period. Over the same period, the number of active customers (LTM) increased by 29.2% to more than 6.2m compared to H1 2024, with an order volume of +39.5% to 5.3m. As a result (including cost efficiency program), adjusted EBITDA rose by 89.6% to € 33.3m (+38.0% vs ODDO BHFe). FCF declined from € 6.3m to -€ 8.3m, mainly due to a higher negative cash flow from investing activities (including M&A).

H1 2025 vs est	imates				
€m	H1 2025	H1 2024	у-о-у	ODDO BHFe	Δ
Net sales	343.0	231.5	+48.2%	345.2	-0.7%
Adj. EBITDA	33.3	17.6	+89.6%	24.1	+38.0%
Margin	9.7%	7.6%	+230bp	7.0%	+270bp
GMV	652.1	442.5	+47.4%	645.8	+1.0%

Sources: ODDO BHF Securities, company

### Performance by segment – more partners and more products drive revenues

The strongest growth in net sales (+72.3% to € 217.2m) and adjusted EBITDA (+138.0% to € 23.4m) was recorded in consumer goods (incl. hood.de, aplanta) which accounted for ca. 63 % of total net sales vs 54% in H1 2024. In the segments of freight goods (+17.3% to € 54.3m), industrial goods (+19.9% to € 38.4m) and service & retail goods (+22.3% to € 33.0m), net sales also improved y-o-y, but at a lower percentage number. In consumer goods, the adjusted EBITDA margin improved by 300bp to 10.8% and in service & retail goods by 230bp to 9.7%, whereas the margin remained flat (4.4%) in industrial goods. The segment of freight goods showed a 30bp decline in the adjusted EBITDA margin to 9.0%.

## Further value creation ahead

TPG confirmed its guidance for 2025: GMV is expected to increase to € 1.3bn and net sales to rise to between € 715m and € 735m. Driven by the positive earnings trend, the successful expansion of the optics & hearing segment (July 2025), and the impact of the cost and efficiency program implemented, adj. EBITDA will increase to between € 54m and € 58m. In the medium-term (2026), the company expects GMV of € 1.6 bn, sales of at least € 860m, and an adj. EBITDA margin of between 7.5% and 10%. As a result, we have increased our 2025e to 2027e sales and adj. EBITDA forecast by an average of 1% and 8% respectively. For 2025e, we are in line with consensus. We confirm our rating (Outperform) and target price (€ 16).

Klaus Breitenbach (Analyst) +49 (0) 69 718 1011

klaus.breitenbach@oddo-bhf.com

### Page 1/5

### Conflict of interests:

ODDO BHF SCA or its subsidiaries and the issuer have agreed on the provision by the first to the second of a service for the production and dissemination of the investment recommendation for said issuer. ODDO BHF SCA and/or one of its subsidiaries could be in a conflict of interest situation with one or several of the issuers mentioned in this publication. Please refer to the conflict of interests section at the end of this document.

## Saturday, August 23, 2025



Page	The Platform Group	Outperform			Price 10.3	35 €	
Same of	Software   Germany	Upside 54.59%					
Seminar   1968							
Constitution	•						
Second company   1.00							
Sey Processor   Sey							
Seminar seminar company   1928   2018   20							
September September   1727   2016   2012							
Temper proof   1908   1909							
Problems (			12/23			12/26e	12/27e
Pinterseption   1,000   1,00							
Memorimentale with profession of the professio						10.35	10.35
Memorimentale with profession of the professio							211
Procession Supers   150   15	•		68.5				
Poutlang							
### Pit							
P.     1.0			0.0				
PCF   10							
NY   1968   19							
Political (Wild)         2.28         0.92         0.89         0.77           Political (Wild)         1.28         0.42         0.93         0.77           Political (Wild)         1.28         0.43         0.43         0.93         0.28           Political (Wild)         1.59         1.50							
Process of the Proc	·						
EXSISTICATION         3.51         0.15         0.35         0.24         2.52         0.25							
CMERNICATION   1988							
Manual Property   Manual Pro							
Sales         448         525         717         802         835           Dipreciation         478         48         49         470         100							
EITDA							
Depreciations							
Current EIFT							
Net branchalistome         4,4         74,6         79,6         79,6           Cerporate Irac         0,4         0,8         11,8         12,2         13,7           Net income dequisysceounted companies         0,0         0,0         0,0         0,0         0,0           Portificities of income dequisysceounted circles (in the part of th							
Corposate To Retination of conjuly-accounted companies         0.04         0.08         1.18         1.12         1.37           Net income of conjuly-accounted companies         0.00         0.0							
Net none of equity-accounted companies   0.0							
Pontinors of discontinued activities (inferental)   100   101	·						
Attributable net profit   31,8   31,2   47,4   27,5   31,0   20,0   31							
Ağııtardı taributable net profit         31.8         31.2         17.4         12.75         12.10           DEALNACE SIETCE         12.22         12.22         12.22         12.22         12.22         12.22         12.22         12.22         12.22         12.22         12.22         12.22         12.22         12.22         12.22         12.22         12.23         47.5	Minority interests		-1.0	-1.6	-1.0	-1.0	-1.0
PALANCE SILET (Fam.)   12/25   12/26   12/25   12/26   12/25   12/26   12/25							
Concepting         438         47.5         47.5         47.5         47.5         47.5         47.5         18.0         27.7         47.5         18.0         27.7         47.5         18.0         18.0         17.6         17.0         77.9         77.8           URC         38.0         37.3         76.0         71.9         71.6         77.0         71.9         71.6         71.0 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>							
Other intangible assets         460         872         91.0         92.7         84.5           Tangible fixed assets         380         73.6         76.0         71.0         71.6           WCR         380         73.6         76.0         71.9         71.6           Financial assets         11.7         20.0         13.2         22.2         22.7         27.7           Ordinary shareholders equity         81.1         13.2         22.2         22.7         27.7           Sharcholders equity         81.1         13.2         22.2         22.7         27.7           Chancerpert provisions         17.0         14.6         14.5         14.6         14.2         14.2         14.2<							
WCR         MCR         7.50         7.10         7.15         7	Other intangible assets		64.0	89.2	91.0	92.7	94.5
Financialsaests							
Ordinaryshareholders equity         805         112         22°         23°         27°           Shareholders equity         816         315         232         241         27°           Non-current provisions         170         146         147         1272							
Minority interests							
Non-current provisions         17.0         14.6         14.6         14.6         14.6         14.6         14.6         14.6         14.6         14.6         14.6         14.6         14.6         14.6         14.6         14.6         14.6         14.6         12.7         12.							
Net debt   1988   101   112   103   101   102   102   102   102   103   101   103   101   103   103   103   105							
1272   1275   1276							
Marie   Mari							
Interests Eaxes   6.6   13.7   2.1   2.6   4.1   1.5   2.2   1.5   2.5   4.1   1.5   2.2   1.5   2.5   1.5   2.5							
Obners         88.7         24.3         -44.6         -17.6         -22.7           Operating Cash flow         104.1         5.79         30.5         4.3         3.88           Free cash-flow         -21.0         -8.1         -8.2         -8.3         -8.4           Free cash-flow         83.0         49.8         22.3         36.0         30.4           Acquisitions/disposals         -58.8         -48.4         -40.0         0.0			-38.0				
Operating Cash flow         104.1         57.9         30.5         44.3         38.8           CAPEX         221.0         8.1         8.2         8.3         8.4           Free cash-flow         33.0         49.8         22.3         36.0         30.4           Acquisitions / disposals         6.8         4.84         4.00         0.0         0.0           Dividends         0.0         0.0         0.0         0.0           Net capital increase         0.0         0.0         0.0         0.0           Others         4.0         0.1         0.0         0.0           Change in net cash         25.3         32.1         11.18         9.8         1.18.5           Change in net cash         12/2 <td>Interests &amp; taxes</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Interests & taxes						
CAPEX         2-10         -8-1         -8-2         -8-3         -8-4           Free cash-flow         830         47-8         -22.3         36.0         30.4           Acquisitions / disposals         -58-8         -48-4         -40.0         0.0         0.0           Dividends         0.0         0.0         0.0         0.0         0.0         0.0           Oth ct capital increase         -40         -1.2         16.5         -15.5         -18.5           Change in et cash         -40         -1.2         16.5         -15.5         -18.5           Change in et cash         -20         -1.2         16.5         -15.5         -18.5           Change in et cash         -20         -1.2         16.5         -15.5         -18.5           Change in et cash         -20         -1.2         16.5         -15.5         -18.5           Change in et cash         -20         -1.2         16.5         -15.5         -18.5         -18.5         -18.5         -18.5         -18.5         -18.5         -18.5         -18.5         -18.5         -18.5         -18.5         -18.5         -18.5         -18.5         -18.5         -18.5         -12.7         -12.7 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>							
Free cash-flow         83.0         49.8         22.3         36.0         30.4           Acquisitions/ disposals         -58.8         48.4         -40.0         0.0							
Dividends         0.0         0.0         0.0         0.0         0.0           Net capital increase         0.0 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
Net capital increase         0.0         0.0         0.0         0.0           Others         -4.0         -1.2         16.5         -15.5         -18.5           Change in net cash         25.3         -3.21         1.18.8         9.8         1.2           CROWIT MARGINS PRODUCTIVITY         12/23         12/24         12/25         12/26         12/27           Sales growth         -         -         1.7.7         52.5%         12.0%            Current EBIT growth         -         -         1.7.7         52.5%         -2.7.8         9.7%           Corwhin adjusted EPS         -         -         1.7.2         52.5%         -2.7.8         9.7%           Net margin         7.4%         5.5%         6.6%         3.4%         3.7%           ReliTDA margin         10.8%         10.6%         11.1%         7.5%         6.6%           CAPEX/ Sales         4.9%         1.5%         1.1%         1.0%         1.0%           VCR/ Sales         8.8         1.40         1.0%         1.0%         1.0%           VCR/ Sales         8.8         1.40         1.0%         1.0%         1.0%           VCR Sales         8.8							
Others         4.0         -1.2         1.15         -1.5.5         -1.8.5           Change in net cash         25.3         -3.2.1         -1.1.8         9.8         1.7.3           GROWTH MARGINSPRODUCTIVITY         12/23         12/24         12/25         12/26         12/26         12/25         12/26         12/26         12/25         12/26         12/26         12/25         12/26         12/25         12/26         12/25         12/26         12/25         12/26         12/25         12/26         12/25         12/26         12/25         12/26         12/25         12/26         12/25 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>							
Change in net cash   25.3   3.21   2.18   9.8   1.3   2.00   2.17   2.							
Sales growth         -         21.4%         36.6%         12.0%         4.5%           Lft sales growth         -							
Lift sales growth         -         9.0%         9.0%         9.0%         -<	GROWTH MARGINS PRODUCTIVITY		12/23				
Current EBIT growth         -         17.7%         52.5%         -27.8%         9.9%           Growth in adjusted EPS         -         -17.2%         52.2%         -42.0%         12.7%           Net margin         7.4%         5.29         6.6%         3.4%         3.7%           EBITDA margin         10.8%         10.6%         11.1%         7.5%         7.8%           CAPEX/Sales         -9.9%         8.7%         9.7%         6.3%         6.6%           VCR/Sales         -1.1%         12.0%         1.1%         -1.0%         1.0%           VCR/Sales         -1.1%         12.2%         19.5%         3.0%         3.0%           Tax Rate         -1.1%         2.2%         19.5%         3.0%         3.0%           Asset Turnover         -2.7         3.1         3.5         3.8           ROCE post-tax (normative tax rate)         -2.7         3.1         3.5         3.8           ROE         -2.7         3.1         3.5         1.7         4           ROE         -2.7         3.1         1.5         1.7         4           ROE post-tax (normative tax rate)         -2.2         2.2         2.2         2.2         2.2			-	21.4%	36.6%	12.0%	4.5%
Growth in adjusted EPS         - 17.2%         52.2%         -42.0%         12.7%           Net margin         7.4%         5.9%         6.6%         3.4%         3.7%           Current EBIT margin         10.8%         10.6%         11.1%         7.5%         8.8%           CAPEX / Sales         -9.0%         8.7%         9.7%         6.6%         6.6%           VCR / Sales         -4.9%         -1.5%         -1.1%         -1.0%         -1.0%           WCR / Sales         4.9%         -1.5%         -1.1%         -1.0%         -1.0%           WCR / Sales         4.9%         1.5%         -1.1%         -1.0%         -1.0%           WCR / Sales         4.9%         1.4%         1.06         -9.0%         8.5%           Tax Rate         8.8%         1.4%         1.06         9.0%         3.0%           Asset Turnover         2.2%         1.0         3.0         3.0%         3.0%         3.0%           ROCE post-tax (normative tax rate)         2.1         2.1         2.1         3.5         3.8         1.74%           ROE         1.0         1.0         1.0         1.0         1.0         1.0         1.0         1.0         1.0	•		-	17 7%	52.5%	-27.0%	9.0%
Net margin         7.4%         5.9%         6.6%         3.4%         3.7%           EBITDA margin         10.8%         11.6%         11.1%         7.5%         7.8%           Current EBIT margin         9.0%         8.7%         9.7%         6.3%         6.6%           CAPEX/Sales         4.9%         1.5%         1.1%         9.0%         8.5%           Tax Rate         1.1%         2.0%         9.0%         3.0%           Normative tax rate         30.0%         30.0%         30.0%         30.0%           Asset Turnover         2.7         3.1         3.5         3.8           ROCE post-tax (normative tax rate)         2.7         2.1         15.6%         17.4%           ROE post-tax (normative tax rate)         2.1         2.7         3.1         15.6%         17.4%           ROE post-tax (normative tax rate)         2.1         2.7         3.1         15.6%         17.4%           ROE post-tax (normative tax rate)         2.1         2.7         3.1         15.6%         17.4%           ROE post-tax (normative tax rate)         2.9         2.0         1.7         2.2         2.2         2.2         2.2         2.2         2.2         2.2         2.2 <td></td> <td></td> <td>-</td> <td></td> <td></td> <td></td> <td></td>			-				
Current EBIT margin         9.0%         8.7%         9.7%         6.3%         6.6%           CAPEX / Sales         -4.9%         -1.5%         -1.1%         -1.0% <td>Net margin</td> <td></td> <td></td> <td>5.9%</td> <td>6.6%</td> <td>3.4%</td> <td>3.7%</td>	Net margin			5.9%	6.6%	3.4%	3.7%
CAPEX/Sales         -4.9%         -1.5%         -1.1%         -1.0%         -1.0%           WCR / Sales         8.8%         14.0%         10.6%         9.0%         8.5%           Tax Rate         -1.1%         2.2%         19.5%         30.0%							
WCR / Sales         8.8%         14.0%         10.6%         9.0%         8.5%           Tax Rate         -1.1%         2.2%         19.5%         30.0%         30.0%           Normative tax rate         30.0%         30.0%         30.0%         30.0%         30.0%           Asset Turnover         -         2.7         3.1         3.5         3.8           ROCE post-tax (normative tax rate)         -         2.1,%         21.4%         15.6%         17.4%           ROE post-tax (normative tax rate)         -         2.9,3%         26.3%         19.7%         22.2%           ROE         -         2.9,3%         26.3%         11.8%         12.2%           ROE         -         2.9,3%         26.3%         11.8%         12.2%           Gearing         84%         74%         48%         43%         37%           Net Obbt / Market Cap         84%         74%         48%         43%         37%           Net Obbt / BITDA         1.81         1.41         1.70         1.5%           EBITDA / net financial charges         7.3         5.9         8.8         6.8         6.8							
Tax Rate         -1.1%         2.2%         19.5%         30.0%         <							
Normative tax rate         30.0% <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
ROCE post-tax (normative tax rate)         1 6.7%         21.4%         15.6%         17.4%           ROCE post-tax hors GW (normative tax rate)         -         21.9%         27.0%         19.7%         22.2%           ROE         -         29.3%         26.3%         11.8%         12.2%           DEBT RATIOS         12/23         12/24         12/25         12/26         12/27           Gearing         84%         74%         48%         43%         37%           Net Oebt / Market Cap         84%         74%         48         43         0.4%           Net Oebt / BITDA / net financial charges         147         1.81         1.41         1.70         1.58           EBITDA / net financial charges         7.3         5.9         8.8         6.8         6.8			30.0%	30.0%	30.0%		
ROCE post-tax hors GW (normative tax rate)         -         21.9%         27.0%         19.7%         22.2%           ROE         -         29.3%         26.3%         11.8%         12.2%           DEBT RATIOS         12/23         12/24         12/25         12/26         12/27           Gearing         84%         74%         48%         43%         37%           Net Debt / Market Cap         0.0         0.53         0.49         0.48           Net debt / BITDA         1.81         1.41         1.70         1.58           BEITDA / net financial charges         7.3         5.9         8.3         6.3         6.8			=				
ROE         -         29.3%         26.3%         11.8%         12.2%           DEBT RATIOS         12/23         12/24         12/25e         12/25e         12/27e           Gearing         84%         74%         48%         43%         37%           Net Debt / Market Cap         0.05         0.5%         0.49         0.48           Net debt / EBITDA         1.47         1.81         1.41         1.70         1.55           EBITDA / net financial charges         7.3         5.9         8.3         6.3         6.8			-				
DEBT RATIOS         12/23         12/24         12/25e         12/26e         12/27e           Gearing Net Debt / Market Cap Net debt / EBITDA         84%         74%         48%         43%         37%           Net debt / FBITDA         0.60         0.53         0.49         0.48           EBITDA / net financial charges         7.3         5.9         8.3         6.3         6.8			-				
Gearing         84%         74%         48%         43%         37%           Net Debt / Market Cap         0.60         0.53         0.49         0.48           Net debt / EBITDA         1.47         1.81         1.41         1.70         1.55           EBITDA / net financial charges         7.3         5.9         8.3         6.3         6.8			12/23				
Net debt / EBITDA         1.47         1.81         1.41         1.70         1.55           EBITDA / net financial charges         7.3         5.9         8.3         6.3         6.8			84%				37%
EBITDA / net financial charges         7.3         5.9         8.3         6.3         6.8			4 47				
			7.0	J.,	0.0	0.0	0.0

Saturday, August 23, 2025



#### Valuation method

Our target prices are established on a 12-month timeframe and we use three valuation methods to determine them. First, the discounting of available cash flows using the discounting parameters set by the Group and indicated on ODDO BHF' website. Second, the sum-of-the-parts method based on the most pertinent financial aggregate depending on the sector of activity. Third, we also use the peer comparison method which facilitates an evaluation of the company relative to similar businesses, either because they operate in identical sectors (and are therefore in competition with one another) or because they benefit from comparable financial dynamics. A mixture of these valuation methods may be used in specific instances to more accurately reflect the specific characteristics of each company covered, thereby fine-tuning its evaluation.

#### • Sensitivity of the result of the analysis/ risk classification:

The opinions expressed in the financial analysis are opinions as per a particular date, i.e. the date indicated in the financial analysis. The recommendation (cf. explanation of the recommendation systematic) can change owing to unforeseeable events which may, for instance, have repercussions on both the company and on the whole industry.

#### · Our stock market recommendations

Our stock market recommendations reflect the RELATIVE performance expected for each stock on a 12-month timeframe. Outperform: performance expected to exceed that of the benchmark index, sectoral (large caps) or other (small and mid caps). Neutral: performance expected to be comparable to that of the benchmark index, sectoral (large caps) or other (small and mid caps). Underperform: performance expected to fall short of that of the benchmark index, sectoral (large caps) or other (small and mid caps).

- The prices of the financial instruments used and mentioned in this document are the closing prices.
- · All publications by ODDO BHF concerning the companies covered and mentioned in this document are available on the research site: www.securities.oddobhf.com/#disclaimer.

Recommendation and target price changes history over the last 12 months for the company analysed in this report				
Date	Reco	Price Target (EUR)	Price (EUR)	Analyst
02/05/25	Outperform	16.00	10.30	Klaus Breitenbach
27/11/24	Outperform	13.50	7.20	Klaus Breitenbach
23/07/24	Outperform	12.50	8.64	Klaus Breitenbach

In accordance with Article 20 of European Regulation No. 596/2014 (Market Abuse Regulation), a list of all recommendations on any financial instrument or issuer that have been disseminated over the past twelve months is available by clicking on the following link www.securities.oddo-bhf.com/# disclaimer.

Recommendation split				
		Outperform	Neutral	Underperform
Our whole coverage	(787)	50%	41%	9%
Liquidity providers coverage	(119)	46%	45%	9%
Research service coverage	(76)	61%	33%	7%
Investment banking services	(47)	64%	32%	4%

If yes, specify the name of the issuers concerned
No
No
If yes, specify the name of the issuers concerned
The Platform Group
If yes, specify the name of the issuers concerned
No

Significant equity stake	If yes, specify the nam of the issuers concern
Does ODDO BHF SCA or its subsidiary ABN AMRO – ODDO BHF B.V. own 1% or more of any class of common equity securities of the subject company/ies?	No
One or more affiliates of ODDO BHF SCA other than ABN AMRO – ODDO BHF B.V. from time to time may own 1% or more of a class of common equity securities of the subject company/ies.	No
Does ODDO BHF SCA or its subsidiary ABN AMRO – ODDO BHF B.V. own a net long or short position of 0.5% or more of any class of common equity securities of the subject company/ies?	No
Does the subject company beneficially own 5% or more of any class of common equity of ODDO BHF SCA or its subsidiary ABN AMRO - ODDO BHF B.V.?	No

## Disclosure to Company

Saturday, August 23, 2025



Has the financial analysis been sent to the issuer for verification prior to publication?	No
Have any modifications been made to the conclusions of the analysis following its verification by the issuer?	No
Additional material conflicts	
Is ODDO BHF SCA or its affiliates aware of any additional material conflict of interest?	No
Personal conflicts of interest	
Do you buy or sell financial instruments from the issuer(s) concerned by this financial analysis?	No
Have those responsible for the drafting of the present document received remuneration directly linked to investment firm service transactions or any other kind of transaction they carry out or any trading commissions they or any legal person who is part of the same group receive?	No

 $Statement\ of\ conflict\ of\ interests\ of\ all\ companies\ mentioned\ in\ this\ document\ may\ be\ consulted\ on\ ODDO\ BHF:\ www.securities.oddo-bhf.com/\# disclaimer.$ 

Saturday, August 23, 2025

#### Disclaimer:



#### Disclaimers for Distribution by ODDO BHF SCA to Non-United States Investors:

This research publication is produced by the Corporates & Markets division of ODDO BHF SCA ("ODDO"), which is licensed by the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and regulated by the Autorité des Marchés Financiers ("AMF").

The research, when distributed outside of the U.S., is intended exclusively for non-U.S. customers of ODDO and cannot be divulged to a third-party without prior written consent of ODDO. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. This research has been prepared in accordance with regulatory provisions designed to promote the independence of investment research. "Chinese walls" (information barriers) have been implemented to avert the unauthorized dissemination of confidential information and to prevent and manage situations of conflict of interest. This research has been prepared in accordance with French regulatory provisions designed to promote the independence of investment research. The recommendation presented in this document is reviewed and updated at least quarterly following each Ouarterly Report published by the issuer that is the subject of this Research Report.

At the time of publication of this document, ODDO and/or one of its subsidiaries may have a conflict of interest with the issuer(s) mentioned. While all reasonable effort has been made to ensure that the information contained is not untrue or misleading at the time of publication, no representation is made as to its accuracy or completeness and it should not be relied upon as such. Past performances offer no guarantee as to future performances. All opinions expressed in the present document reflect the current context which is subject to change without notice. The views expressed in this Research Report accurately reflect the analyst's personal views about the subject securities and/or issuers and no part of his compensation was, is, or will be directly or indirectly related to the specific views contained in the Research Report. This Research Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice.

This Research Report is for institutional investors only. It may not contain information necessary for others to make investment decisions. Consult your financial adviser or an investment professional if you are not an institutional investor.

#### Disclaimers for Distribution by ODDO BHF New York Corporation to United States Investors:

This Research Report is produced by ODDO BHF Corporates & Markets, a division of ODDO. This research is distributed to U.S. investors exclusively by ODDO BHF New York Corporation ("ONY"), MEMBER: FINRA/SIPC, and is intended exclusively for U.S. customers of ONY and cannot be divulged to a third-party without prior written consent of ONY. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. This research has been prepared in accordance with regulatory provisions designed to promote the independence of investment research. "Chinese walls" (information barriers) have been implemented to avert the unauthorized dissemination of confidential information and to prevent and manage situations of conflict of interest. This research has been prepared in accordance with French regulatory provisions designed to promote the independence of investment research. The recommendation presented in this document is reviewed and updated at least quarterly following each Quarterly Report published by the issuer that is the subject of this Research Report.

At the time of publication of this document, ODDO, and/or one of its subsidiaries may have a conflict of interest with the issuer(s) mentioned. While all reasonable effort has been made to ensure that the information contained is not untrue or misleading at the time of publication, no representation is made as to its accuracy or completeness and it should not be relied upon as such. Past performances offer no guarantee as to future performances. All opinions expressed in the present document reflect the current context which is subject to change without notice. The views expressed in this Research Report accurately reflect the analyst's personal views about the subject securities and/or issuers and no part of his compensation was, is, or will be directly or indirectly related to the specific views contained in the Research Report. This Research Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice.

This Research Report is for institutional investors only. It may not contain information necessary for others to make investment decisions. Consult your financial adviser or an investment professional if you are not an institutional investor.

Disclosures Required by United States Laws and Regulations:

Rule 15a-6 Disclosure: Under Rule 15a-6(a)(3), any transactions conducted by ODDO, and/or one of its subsidiaries with U.S. persons in the securities described in this foreign research must be effected through ONY. As a member of FINRA, ONY has reviewed this material for distribution to U.S. persons as required by FINRA Rules 2241(h) applicable to dissemination of research produced by its affiliate ODDO.

### FINRA Disclosures:

- Neither ONY, ODDO, nor ODDO BHF Corporates & Markets beneficially owns 1% or more of any class of common equity securities of the subject company.
- The research analyst of ODDO BHF Corporates & Markets, at the time of publication of this research report, is not aware, nor does he or she know or have reason to know of any actual, material conflict of interest of himself or herself, ODDO, ODDO BHF Corporates & Markets or ONY, except those mentioned in the paragraph entitled "Risks of Conflicts of Interest"
- ODDO BHF Corporates & Markets or ODDO may receive or seek compensation for investment banking services in the next 3 months from the subject company of this Research Report, but ONY would not participate in those arrangements.
- Neither ONY, ODDO, ODDO BHF Corporates & Markets has received compensation from the subject company in the past 12 months for providing investment banking services except those mentioned in the paragraph of "Risks of Conflict of Interest"."
- Neither ONY, ODDO, ODDO BHF Corporates & Markets has managed or co-managed a public offering of securities for the subject company in the past 12 months except those mentioned in the paragraph of "Risk of Conflict of Interest".
- ONY does not make (and never has made) markets and, accordingly, was not making a market in the subject company's securities at the time that this research report was published.

### Regulation AC:

ONY is exempt from the certification requirements of Regulation AC for its distribution to a U.S. person in the United States of this Research Report that is prepared by an ODDO BHF Corporates & Markets research analyst because ODDO has no officers or persons performing similar functions or employees in common with ONY and ONY maintains and enforces written policies and procedures reasonably designed to prevent it, any controlling persons, officers or persons performing similar functions, and employees of ONY from influencing the activities of the third party research analyst and the content of research reports prepared by the third party research analyst.

Contact Information of firm distributing research to U.S. investors: ODDO BHF New York Corporation, MEMBER: FINRA/SIPC, is a wholly owned subsidiary of ODDO BHF SCA; Louis paul ROGER, President (louis-paul.roger@oddo-bhf.com) 150 East 52nd Street New York, NY 10022 646-286-2137.

Statement of conflict of interests of all companies mentioned in this document may be consulted on Oddo BHF research site.